Skip to main content

Zymeworks Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ZYME$31.46+2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Lossand Comprehensive

Condensed Consolidated Statements of Loss and Comprehensive Loss

(Expressed in thousands of U.S. dollars except share and per share data)

Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue
Research and development collaborations (note 9)$27,614$16,000$103,450$45,273
Operating expenses:
Research and development35,57836,353105,76597,558
General and administrative14,14613,85246,08245,321
Impairment on acquired IPR&D (note 6)———17,287
Total operating expenses49,72450,205151,847160,166
Loss from operations(22,110)(34,205)(48,397)(114,893)
Other income:
Interest income3,5294,78510,37915,859
Other income (expense), net (note 10)315(204)(257)214
Total other income, net3,8444,58110,12216,073
Loss before income taxes(18,266)(29,624)(38,275)(98,820)
Income tax expense(1,336)(226)(1,646)(369)
Net loss(19,602)(29,850)$(39,921)$(99,189)
Other comprehensive income:
Unrealized income on available for sale securities, net of tax of nil (note 5)2901,905902604
Total other comprehensive income2901,905902604
Comprehensive loss$(19,312)$(27,945)$(39,019)$(98,585)
Net loss per common share (note 4):
Basic$(0.26)$(0.39)$(0.53)$(1.30)
Diluted$(0.26)$(0.39)$(0.53)$(1.30)
Weighted-average common stock outstanding (note 4):
Basic75,767,77876,128,53175,427,50876,244,893
Diluted75,775,21476,157,10175,434,48776,266,177
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.